eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2006
vol. 1
 
Share:
Share:
abstract:

Review paper
Systemic therapy in the treatment of gastroenteropancreatic neuroendocrine tumors

Andrzej Deptała
,
Alicja Asendrych
,
Joanna Omyła-Staszewska
,
Joanna Rzymkowska

Przegl Gastroenterol 2006; 1, 1: 10-15
Online publish date: 2006/03/31
View full text Get citation
 
Neuroendocrine tumors (NET) of the gastrointestinal system represent a group of heterogeneous cancers derived from various endocrine cells located in the stomach, guts and pancreas (GEP). Therapy of GEP NET, due to their biological diversity and different clinical course of each of the tumors, became an interdisciplinary approach with the contribution of a variety of specialists, e.g.: surgeons, endocrinologists, oncologists, nuclear medicine experts, radiologists, and transplantologists. Surgical resection of GEP NET without metastases and limited to one organ is the treatment of choice, because such procedure offers the highest probability of cure. Based on the current evidence in medicine, there is no proof that any adjuvant therapy prolongs disease free- and overall survival. Systemic treatment of GEP NET relies on the application of biological therapy (somatostatin analogs, interferon alfa – IFNα) and/or chemotherapy. “Cold” (i.e. unconjugated) somatostatin analogs (SSTA) are the gold standard of management of symptoms in GEP NET. Treatment of GEP NET with IFNα allows similar to SSTA symptomatic and biochemical responses. Chemotherapy using two/three drug combinations (polychemotherapy) gives the best results in the pancreatic NET. In the treatment of midgut carcinoid tumors chemotherapy is less effective.
keywords:

neuroendocrine tumors, gastroenteropancreatic tumors, GEP NET, chemotherapy, targeted therapy

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.